These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 9093725)

  • 21. Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in Non-Small Cell Lung Cancer Stage IIIB/IV.
    Maneechawakajorn J; Hathaisanguan S
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S175-81. PubMed ID: 27266233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer.
    Au E; Koo WH; Tan EH; Ang PT
    J Chemother; 1996 Aug; 8(4):300-3. PubMed ID: 8873837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
    Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
    Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Poon MA; O'Connell MJ; Moertel CG; Wieand HS; Cullinan SA; Everson LK; Krook JE; Mailliard JA; Laurie JA; Tschetter LK
    J Clin Oncol; 1989 Oct; 7(10):1407-18. PubMed ID: 2476530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.
    Cascinu S; Fedeli A; Catalano G
    Cancer Chemother Pharmacol; 1994; 34(1):72-4. PubMed ID: 8174205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
    Bjarnason GA; Cripps C; Goel R; Fine S; Oza AM; Skillings JR; Kerr I; Germond CJ; Moore MJ; Maroun JA; Franssen E; Dulude H
    Am J Clin Oncol; 1998 Dec; 21(6):537-42. PubMed ID: 9856651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chemotherapy of scirrhous gastric cancer].
    Wakui A
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2398-406. PubMed ID: 7944483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers.
    Schulze-Bergkamen H; Zuna I; Teufel A; Stremmel W; Rudi J
    Med Oncol; 2002; 19(1):43-53. PubMed ID: 12025890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.
    Papadakou M; Xydakis E; Bonios M; Makropoulou E; Boukis C; Kakavoulis T; Karaliotas C; Panagos G
    J BUON; 2006; 11(3):285-9. PubMed ID: 17309151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
    Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
    J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
    Brenner B; Shah MA; Karpeh MS; Gonen M; Brennan MF; Coit DG; Klimstra DS; Tang LH; Kelsen DP
    Ann Oncol; 2006 Sep; 17(9):1404-11. PubMed ID: 16788003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.
    Barone C; Corsi DC; Pozzo C; Cassano A; Fontana T; Noviello MR; Landriscina M; Colloca G; Astone A
    Cancer; 1998 Apr; 82(8):1460-7. PubMed ID: 9554521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation.
    Chao Y; Teng HC; Hung HC; King KL; Li CP; Chi KH; Yen SH; Chang FY
    Jpn J Clin Oncol; 2000 Mar; 30(3):122-5. PubMed ID: 10798538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide.
    Taal BG; Teller FG; ten Bokkel Huinink WW; Boot H; Beijnen JH; Dubbelman R
    Ann Oncol; 1994 Jan; 5(1):90-2. PubMed ID: 8172800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
    Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
    Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
    Lou F; Zhu YH; Pan HM
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):75-8. PubMed ID: 19538878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
    Rosati G; Cordio S; Caputo G; Condorelli S; Germano D; Mattina M; Amadio P; Reggiardo G; Manzione L
    J Chemother; 2007 Oct; 19(5):570-6. PubMed ID: 18073157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.